Nesfatin-1 in advanced lung cancer patients with weight loss
Regulatory Peptides, cilt.181, sa.1, ss.1-3, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 181 Sayı: 1
- Basım Tarihi: 2013
- Doi Numarası: 10.1016/j.regpep.2012.11.005
- Dergi Adı: Regulatory Peptides
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1-3
- Anahtar Kelimeler: Nesfatin, Lung cancer, Weight loss, Cachexia
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
The cachexia occurs frequently in lung cancer patients. Among appetite regulatory peptides, alteration of expressions of leptin and ghrelin is demonstrated in cachectic cancer patients, but nesfatin-1 has not been yet studied in cancer. We investigated serum nesfatin-1 level in advanced lung cancer patients.Forty-one lung cancer patients and 24 healthy subjects were included to the study. Nesfatin-1 serum levels were analyzed by ELISA kit.Serum nesfatin-1 levels were lower in lung cancer patients than in healthy subjects (0.52 ± 0.19. ng/ml vs 0.75 ± 0.23. ng/ml; p < 0.001). In lung cancer patients with weight loss, nesfatin-1 levels were decreased compared to the patients without weight loss (0.44 ± 0.16. ng/ml vs 0.63 ± 0.18. ng/ml; p < 0.001). Whereas, there were no any difference between patients without weight loss and control subjects (0.63 ± 0.18. ng/ml vs 0.75 ± 0.23. ng/ml; p:0.129) or between SCLC and NSCLC patients (0.53 ± 0.18. ng/ml vs 0.52 ± 0.20. ng/ml; p:0.458). No significant correlation was found between serum nesfatin-1 values and BMI.In conclusion, loss of fat mass may decrease serum nesfatin-1 level in lung cancer patients with weight loss. The future studies which explore biological significance of low serum nesfatin-1 level in cancer are needed. © 2012 Elsevier B.V.